Bristol Myers Squibb Raised 2026 Targets After Q2 Sales Jumped to $13 Billion

Bristol Myers Squibb reset 2026 expectations with a strong Q2

This quarter changed the conversation around Bristol Myers Squibb.

Just as investors were getting ready to treat BMS as a company living off prior hits, it reported Q2 2026 revenues of $13.0 billion, up 6% year-over-year, and raised its full-year outlook. Management now expects $49.0 billion to $50.0 billion in 2026 revenue, versus the prior $46 billion to $47.5 billion range, while non-GAAP EPS guidance increased to $6.75 to $7.00 from $6.05 to $6.35. That is more than a solid quarter; it is a meaningful reset in expectations for the year.

The improvement also looked broader than a one-day surprise. Earnings rose to non-GAAP EPS of $2.04 from $1.46 a year earlier, and the growth portfolio contributed $7.6 billion, now nearly 60% of total revenue. In simple terms, a larger share of BMS sales is coming from newer, faster-growing products rather than from a maturing legacy portfolio.

One quarter does not prove a full turnaround, and guidance can always miss. As the company says, forward-looking statements are not guaranteed. Still, this release gave investors a clearer reason to reconsider the stock.

Growth Portfolio mix is becoming the real story

The most important change is revenue composition.

BMS still has legacy products to manage, but its Growth Portfolio revenues of $7.6 billion now represent nearly 60% of total revenue and grew 15% year over year. That matters because higher valuations usually follow when future earnings come from newer growth engines rather than from a declining base.

Several products helped drive the quarter

This was not dependent on a single drug. The company pointed to broad-based momentum across the portfolio, including contributions from key brands such as Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, and Opdualag. Breyanzi also stood out because growth came from demand across approved indications in the U.S. and international markets, which suggests current-label expansion rather than a short-lived launch spike.

Margin discipline makes the shift more credible

The profit profile also held up. Non-GAAP gross margin was 71.4%, and full-year operating expenses are still guided at about $16.5 billion even with more investment in launches. That suggests the newer portfolio is helping offset legacy decline without requiring a major sacrifice in profitability.

What would validate the raised guidance

A higher guide is an opportunity, not a finish line. After the full-year revenue target increase to $49.0 billion to $50.0 billion and the non-GAAP EPS outlook raised to $6.75 to $7.00, the next step is to see whether this was the start of a cleaner earnings base or simply a very strong quarter. As the company notes, forward-looking statements are not guaranteed.

Eliquis remains a major part of the equation

The clearest watchpoint is concentration. BMS now expects worldwide Eliquis revenue growth of 20% to 25% while still expecting legacy portfolio revenue decline of 4% to 6%. That is positive for the overall outlook, but it also means a large part of the math still depends on Eliquis holding its pace.

Two signals to monitor next

What would strengthen the bull case is seeing multiple growth drivers continue to help support the raised target. A few follow-through reports across the broader portfolio would make the reset look more durable. If that does not happen, the quarter may still look good on its own while leaving the longer-term story less resolved.